TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8667171

Group type: EXPERIMENTAL
Intervention: Repressers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonrepressers
Number of subjects: 0
Study: 1416115

Group type: EXPERIMENTAL
Intervention: Preoperative normovolemic hemodilution (PNH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No PNH (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aortic clamping
Number of subjects: 20
Study: 3917264

Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms b.i.d. for 5 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enprostil 7 micrograms b.i.d. for 5 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30563934

Group type: EXPERIMENTAL
Intervention: Afuresertib at 125 mg/day with intravenous paclitaxel (175 mg/m2) and carboplatin (AUC5) every 3 weeks for six cycles followed by maintenance afuresertib at 125 mg/day
Number of subjects: 59
Study: 27706120

Group type: EXPERIMENTAL
Intervention: Nasal spray containing liposomes, vitamins A and E (experimental arm group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline solution (sodium chloride 0.9%) (control arm group II)
Number of subjects: 40
Study: 26525391

Group type: EXPERIMENTAL
Intervention: Polypharmacy (use of five or more drugs)
Number of subjects: 4056

Group type: COMPARATOR
Intervention: No polypharmacy (less than five drugs)
Number of subjects: 4056

Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 4056

Group type: EXPERIMENTAL
Intervention: Number of drugs
Number of subjects: 4056
Study: 25132863

Group type: EXPERIMENTAL
Intervention: Type of endotracheal tube A
Number of subjects: 6

Group type: COMPARATOR
Intervention: Type of endotracheal tube B
Number of subjects: 6
Study: 22607295

Group type: EXPERIMENTAL
Intervention: Resin salve treatment
Number of subjects: 23
Study: 19641054

Group type: COMPARATOR
Intervention: Pregabalin 300 mg administered perioperatively, 12 hours apart.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 0
Study: 17620739

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) - 20 treatments at 2.0 ATA for 90 minutes
Number of subjects: 6
Study: 16305082

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) stimulation for 8 hours/day starting at day 10 after surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-stimulated sites
Number of subjects: 30
Study: 16861258

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% (2.2 ml) heavy with clonidine (75 microg) in 0.5 ml normal saline 0.9% (BC)
Number of subjects: 106

Group type: COMPARATOR
Intervention: bupivacaine 0.5% (2.2 ml) heavy with 0.5 ml normal saline 0.9% (B)
Number of subjects: 106
Study: 10577295

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/d)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 8893536

Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (PR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 72
Study: 2049311

Group type: EXPERIMENTAL
Intervention: Chlorambucil (10 mg daily for six weeks, then alternating fortnights for 12 weeks) + Interferon-alpha 2b (2 x 10(6) U/m2 three times weekly for 18 weeks)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Maintenance Interferon-alpha 2b
Number of subjects: 124

Group type: COMPARATOR
Intervention: Chlorambucil alone
Number of subjects: 124
Study: 6301364

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (250 mg, single intramuscular dose)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Aqueous procaine penicillin G (4.8 X 10(6) U, two intramuscular doses)
Number of subjects: 51
Study: 27091833

Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 134

Group type: COMPARATOR
Intervention: Untrained GPs
Number of subjects: 134
Study: 30466850

Group type: EXPERIMENTAL
Intervention: Cryoballoon-based pulmonary vein isolation (PVI)
Number of subjects: 101
Study: 26461925

Group type: COMPARATOR
Intervention: Activity group
Number of subjects: 36
Study: 25150607

Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation with pressure support (P-SIMV)
Number of subjects: 0
Study: 22309847

Group type: EXPERIMENTAL
Intervention: Commercially available pressure relieving and thermally insulating insole
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham insole with no cushioning or thermal properties
Number of subjects: 140
Study: 20808298

Group type: EXPERIMENTAL
Intervention: Regular use of aspirin (≥ 4 times/month)
Number of subjects: 42393

Group type: EXPERIMENTAL
Intervention: Heavy use of combined aspirin and ibuprofen (≥ 2 times/day) in males
Number of subjects: 42393

Group type: EXPERIMENTAL
Intervention: Regular use of NSAIDs in females with BMI <25
Number of subjects: 42393

Group type: EXPERIMENTAL
Intervention: Regular use of ibuprofen
Number of subjects: 42393

Group type: EXPERIMENTAL
Intervention: Age group 70-74 years
Number of subjects: 42393
Study: 17950096

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Losartan 100 mg + amlodipine 5 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 21
Study: 15630735

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 1902

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 1902
Study: 12241530

Group type: EXPERIMENTAL
Intervention: Vitamin C (1.5 g daily in three doses for 3 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 3 weeks)
Number of subjects: 35
Study: 10404801

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg orally once daily for 6 months (group 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 18
Study: 8552122

Group type: EXPERIMENTAL
Intervention: 1 mg pergolide
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10 mg bromocriptine
Number of subjects: 12
Study: 31359368

Group type: EXPERIMENTAL
Intervention: iGlarLixi (60 units/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iGlarLixi (< 60 units/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: iGlar (60 units/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: iGlar (< 60 units/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iGlarLixi (60 or < 60 units/day)
Number of subjects: 0
Study: 27987224

Group type: EXPERIMENTAL
Intervention: Mobile cooperation intervention (mobile application‐assisted cooperation and training in the functions of the mobile application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard cooperation (control group)
Number of subjects: 0
Study: 25877711

Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium eye drops, twice a day for three days before surgery and one day after surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.5% ketorolac tromethamine eye drops, four times a day for three days before surgery and one day after surgery
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium eye drops
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.5% ketorolac tromethamine eye drops
Number of subjects: 64
Study: 23636449

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Warfarin 1 mg/day
Number of subjects: 420

Group type: COMPARATOR
Intervention: No anticoagulant prophylaxis
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Anticoagulation (both LMWH and Warfarin)
Number of subjects: 420
Study: 22012500

Group type: EXPERIMENTAL
Intervention: Pitchback exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PNF D2 pattern with tubing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Push-up plus exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slide board exercise
Number of subjects: 0
Study: 18722818

Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual graded activity
Number of subjects: 8
Study: 16415628

Group type: EXPERIMENTAL
Intervention: Behavioral intervention program combining pelvic floor muscle exercise with bladder training (4 weeks, once a week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Behavioral intervention program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Follow-up assessment (9th week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Follow-up assessment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 12215470

Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring (hyperbaric index)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Office blood pressure measurements
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 403

Group type: COMPARATOR
Intervention: Normotensive pregnancies
Number of subjects: 403
Study: 10473014

Group type: EXPERIMENTAL
Intervention: Volunteer-support (VS), N = 52
Number of subjects: 106

Group type: COMPARATOR
Intervention: Office-based (OB), N = 54
Number of subjects: 106
Study: 8904740

Group type: EXPERIMENTAL
Intervention: Pregnanolone (two different formulations)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (not administered in this study)
Number of subjects: 18
Study: 1680325

Group type: EXPERIMENTAL
Intervention: Ridazolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6406699

Group type: EXPERIMENTAL
Intervention: 40% zinc oxide ointment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Plain petrolatum ointment
Number of subjects: 9
Study: 30772148

Group type: EXPERIMENTAL
Intervention: Green space intervention
Number of subjects: 931

Group type: COMPARATOR
Intervention: Control group (traditional playground)
Number of subjects: 931
Study: 30400588

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei (LP)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum (LF)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei (LP) + Lactobacillus fermentum (LF)
Number of subjects: 160
Study: 26718808

Group type: EXPERIMENTAL
Intervention: 600 μg oral misoprostol
Number of subjects: 1820

Group type: COMPARATOR
Intervention: 10 IU oxytocin in Uniject (intramuscular)
Number of subjects: 1820
Study: 25098777

Group type: EXPERIMENTAL
Intervention: Full-dose US group (0.5 ml/kg LA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 30% reduced dose LA (0.35 ml/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 50% reduced dose LA (0.25 ml/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 70% reduced dose LA (0.15 ml/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neurostimulation alone group (0.5 ml/kg LA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups (FD, 30, NS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Full-dose group
Number of subjects: 100
Study: 22448716

Group type: EXPERIMENTAL
Intervention: Transfemoral aortic valve implantation (TAVI)
Number of subjects: 30
Study: 18706549

Group type: EXPERIMENTAL
Intervention: Long letrozole therapy (n = 108; 219 cycles)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Short letrozole therapy (n = 110; 225 cycles)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Long letrozole therapy
Number of subjects: 218

Group type: COMPARATOR
Intervention: Short letrozole therapy
Number of subjects: 218
Study: 19001352

Group type: EXPERIMENTAL
Intervention: GIST (group, individual, and staff therapy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 25
Study: 16041534

Group type: EXPERIMENTAL
Intervention: biperiden (2 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: rivastigmine (3 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 11828049

Group type: EXPERIMENTAL
Intervention: Hospital at Home (HaH) care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 60
Study: 10407599

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg monthly doses)
Number of subjects: 100
Study: 7574954

Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (37 degrees C)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Mild hypothermic blood cardioplegia (28 degrees to 29 degrees C)
Number of subjects: 101
Study: 2147752

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily (with doubling of dosage at week 6 if LDL-cholesterol > 1.40 g/l)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg twice daily (with doubling of dosage at week 6 if LDL-cholesterol > 1.40 g/l)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 184

Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 184
Study: 7438715

Group type: EXPERIMENTAL
Intervention: Methionine enkephalin analogue DAMME infusion
Number of subjects: 0
Study: 30977273

Group type: EXPERIMENTAL
Intervention: 600 mg NAC syrup, orally once daily at night for 7 consecutive days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo, administered similarly to NAC
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: NAC and Placebo
Number of subjects: 57
Study: 29529622

Group type: EXPERIMENTAL
Intervention: Patellofemoral arthroplasty (PFA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 100
Study: 27279274

Group type: EXPERIMENTAL
Intervention: Fish oil (FO, n = 63)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FSO, n = 61)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Corn oil (control, n = 61)
Number of subjects: 185
Study: 25157647

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 150
Study: 22761293

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine for 7‐11 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20061261

Group type: EXPERIMENTAL
Intervention: In Our Own Voice (IOOV) presentation
Number of subjects: 30
Study: 18076241

Group type: EXPERIMENTAL
Intervention: Immersion to the hip
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Immersion to the breast
Number of subjects: 16

Group type: COMPARATOR
Intervention: On land
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 16
Study: 16318659

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5% 10 mg (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 0.5% 17.5 mg (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group without spinal anaesthesia (Group III)
Number of subjects: 60
Study: 12393618

Group type: EXPERIMENTAL
Intervention: FND (Fludarabine, mitoxantrone, dexamethasone)
Number of subjects: 142

Group type: COMPARATOR
Intervention: ATT (alternating triple therapy)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: FND
Number of subjects: 142

Group type: COMPARATOR
Intervention: ATT
Number of subjects: 142
Study: 10332682

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 113

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 113
Study: 8565029

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg twice daily
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254

Group type: COMPARATOR
Intervention: Etodolac vs Placebo
Number of subjects: 254

Group type: COMPARATOR
Intervention: Naproxen vs Placebo
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Etodolac and Naproxen
Number of subjects: 254
Study: 1785706

Group type: EXPERIMENTAL
Intervention: Cell Saver 1V (Haemonetics)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ultrafiltration
Number of subjects: 120
Study: 7180619

Group type: EXPERIMENTAL
Intervention: Cigarette smoking and alcohol consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-deprived smokers
Number of subjects: 0
Study: 28786547

Group type: EXPERIMENTAL
Intervention: semaglutide 0.5 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: sitagliptin 100 mg
Number of subjects: 308
Study: 26353789

Group type: EXPERIMENTAL
Intervention: High-dose fish oil (4.5 g omega-3 fatty acids) 15 mL/day
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low-dose fish oil (blend of fish oil and sunola oil; ratio of 1:9, 0.45 g omega-3 fatty acids) 15 mL/day
Number of subjects: 202
Study: 24325591

Group type: EXPERIMENTAL
Intervention: EUS‐FNB
Number of subjects: 28

Group type: COMPARATOR
Intervention: EUS‐FNA
Number of subjects: 28
Study: 23879825

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) in addition to conventional medical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 0
Study: 20523087

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 on day 1 with gemcitabine 1,250 mg/m2 on days 1 and 8 (arm A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 on day 8 with gemcitabine 1,250 mg/m2 on days 1 and 8 (arm B)
Number of subjects: 71
Study: 18444053

Group type: EXPERIMENTAL
Intervention: Maudsley model of family therapy for anorexia nervosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for bulimia nervosa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other psychosocial interventions (family therapy, cognitive therapy, behavioral therapy)
Number of subjects: 0
Study: 16620243

Group type: EXPERIMENTAL
Intervention: Individualized nursing case management with access to a nurse case manager 24/7 and an abuse video (N = 499)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Nursing care management activities (support and assessing needs)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1000
Study: 14669180

Group type: EXPERIMENTAL
Intervention: Structured speed‐dependent treadmill training (STT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Limited progressive treadmill training (LTT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional gait training (CGT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 17
Study: 10946099

Group type: EXPERIMENTAL
Intervention: Isometric trunk extension‐flexion test with different heights for the pelvic fulcrum
Number of subjects: 114

Group type: COMPARATOR
Intervention: Isometric trunk extension‐flexion test with pelvic fulcrum at hip joint level
Number of subjects: 114
Study: 8823423

Group type: EXPERIMENTAL
Intervention: Additional doses of rifampicin, pyrazinamide and streptomycin every 4 weeks in the continuation phase (114 patients)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard regimen without additional doses (113 patients)
Number of subjects: 266
Study: 1395977

Group type: EXPERIMENTAL
Intervention: Corticosteroid enemas (CS‐‐100 mg of hydrocortisone/60 cc P.R. q.h.s.; n = 12)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mesalamine enemas (5‐ASA‐‐4 g/60 cc P.R. q.h.s.; n = 19)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Short-chain fatty acid enemas (SCFA‐‐60 cc P.R. b.i.d.; n = 14)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cost of treatment for corticosteroid enemas
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cost of treatment for mesalamine enemas
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cost of treatment for short-chain fatty acid enemas
Number of subjects: 45
Study: 2857601

Group type: EXPERIMENTAL
Intervention: Intravenous pinacidil, 0.2 mg/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hydralazine, 0.3 mg/kg
Number of subjects: 6
Study: 31619413

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 1278
Study: 28956187

Group type: EXPERIMENTAL
Intervention: Schedule A: every-3-week ixabepilone (32 mg/m2 on day 2) + vorinostat (300 mg daily, days 1-14)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Schedule B: weekly ixabepilone (16 mg/m2 on days 2, 9, 16) + vorinostat (300 mg daily, days 1-7; 15-21)
Number of subjects: 37
Study: 26745614

Group type: EXPERIMENTAL
Intervention: Collagen Matrix (CM)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Extracellular Matrix (ECM)
Number of subjects: 23
Study: 25358221

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily before meal for 4 consecutive days monthly for 3 months
Number of subjects: 386

Group type: COMPARATOR
Intervention: Doxycycline 100 mg daily after meals for 3 months
Number of subjects: 386
Study: 22680315

Group type: EXPERIMENTAL
Intervention: Screened volunteers
Number of subjects: 156

Group type: COMPARATOR
Intervention: Non-randomized volunteers
Number of subjects: 156
Study: 20182883

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 0.5 ml dexamethasone diphosphate (10 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0.5 ml placebo
Number of subjects: 34
Study: 19087677

Group type: EXPERIMENTAL
Intervention: TXL capsule
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 70
Study: 17469415

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) for therapeutic indications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive methods for post-ERCP pancreatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreatic endotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interdisciplinary team approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of unestablished methods
Number of subjects: 0
Study: 12032630

Group type: EXPERIMENTAL
Intervention: Sodium restriction (50 mmol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Liberal sodium intake (200 mmol)
Number of subjects: 24
Study: 10191222

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7473519

Group type: EXPERIMENTAL
Intervention: Drug treatment for hypertension
Number of subjects: 850
Study: 1915197

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Large neutral amino acids (LNAA)
Number of subjects: 8